What happened According to an SEC filing dated Feb. 17, 2026, RTW Investments disclosed a new position in iRhythm Holdings (NASDAQ:IRTC) after acquiring 1,181,990 shares during the fourth quarter. The fund’s quarter-end position in IRTC was valued at $210 million. What else to know This is a new position for RTW Investments, representing 2.1% of its $9.98 billion 13F reportable assets under management as of Dec. 31, 2025. Top five holdings after the filing: NASDAQ:MDGL: $1.2 billion (11.6% of AUM) ...

Core Insights - iRhythm Holdings, Inc. has appointed Jason Patten to its Board of Directors, effective March 12, 2026, enhancing its strategic leadership in healthcare [2][3] - The company aims to transition from episodic detection to proactive, integrated, and predictive care, leveraging Patten's extensive experience in enterprise strategy and innovation [3] Company Overview - iRhythm is a digital health care company focused on creating solutions that detect, predict, and prevent disease through wearable biosensors and cloud-based data analytics [7] - The company's vision is to provide better data, insights, and health outcomes for patients [7] Jason Patten's Background - Jason Patten currently serves as Executive Vice President and Head of Enterprise Strategy at UnitedHealth Group, leading corporate strategy and innovation [4] - His previous roles include Chief Operating Officer and Senior Vice President of OptumHealth, where he optimized business performance and operational strategy [4][5] - Patten has a strong foundation in financial services and marketing, with experience in global product development and strategic marketing [5][6]

Core Insights - iRhythm Holdings, Inc. (NASDAQ:IRTC) is recognized as one of the fastest growing mid-cap stocks, with significant revenue growth and positive profitability metrics reported for Q4 2025 [1][2]. Financial Performance - For Q4 2025, iRhythm reported revenue of $208.9 million, marking a 27.1% increase year-over-year. The company achieved a net income of $5.6 million and a gross margin of 70.9%, indicating its first quarter of positive GAAP profitability [3][8]. - The total revenue for the full year 2025 reached $747.1 million, reflecting a 26.2% annual growth. The gross margin slightly decreased to 70.6%, while the net loss improved to $44.6 million compared to the previous year. Notably, the company generated positive free cash flow of $34.5 million for the first time in a full year [4]. Business Model and Strategy - iRhythm is a digital healthcare company specializing in cardiac monitoring solutions, utilizing its flagship Zio platform, which incorporates wearable biosensors and AI-driven analytics to enhance the diagnosis of heart conditions [5]. - The company attributes its success to innovative care channels, expansion into international markets, and sustained demand within its core U.S. business, with a focus on growth, margin expansion, and prudent investment as it approaches 2026 [4].

Core Insights - Artisan Partners released its fourth-quarter 2025 investor letter for the Artisan Mid Cap Fund, which focuses on investing in companies with strong earnings and trading at a discount to their estimated private market value [1] - The Fund's Investor Class, ARTMX, delivered a return of -0.44%, while the Advisor Class, APDMX, and Institutional Class, APHMX, returned -0.37% and -0.35% respectively, compared to -3.70% for the Russell Midcap® Growth Index [1] - The performance was bolstered by strength in the information technology and healthcare sectors [1] Company-Specific Insights - IRhythm Holdings, Inc. (NASDAQ:IRTC) is highlighted as a key stock in the Artisan Mid Cap Fund's fourth-quarter letter, providing Zio ambulatory cardiac monitoring services [2] - As of February 23, 2026, IRhythm's stock closed at $141.22, with a one-month return of -9.80% and a 52-week gain of 23.98%, giving it a market capitalization of $4.55 billion [2] - The Fund noted that IRhythm experienced solid growth in its core services and improving cash flow trends, leading to a decision to trim the position to take profits after a strong 2025 [3] - The company is not among the 30 most popular stocks among hedge funds, with 44 hedge fund portfolios holding its shares at the end of the fourth quarter, an increase from 43 in the previous quarter [4]

Core Insights - iRhythm Technologies, Inc. specializes in cardiac monitoring solutions, particularly known for its Zio service, which detects cardiac arrhythmias [1] - The company is actively competing in the healthcare technology sector, focusing on technological advancements and strategic growth to maintain its market position [1] Stock Performance - On February 20, 2026, William Blair upgraded iRhythm's stock to a "Buy" rating, with the stock priced at $150.97, indicating confidence in the company's potential despite recent challenges [2] - Currently, iRhythm's stock is priced at $151.85, experiencing a 4.42% decrease today, with a trading range between $145.49 and $164.69 [4] - Over the past year, the stock has seen significant fluctuations, with a high of $212 and a low of $92.52 [4] Financial Metrics - iRhythm's market capitalization is approximately $4.89 billion, with a trading volume of 1,445,876 shares, reflecting strong market presence and investor interest [5][6] - The Q4 2025 earnings call provided insights into the company's financial performance and strategic direction, crucial for understanding its future prospects [3][6]

Core Insights - iRhythm Technologies reported a "breakout year" for 2025, with significant revenue growth, margin expansion, and its first positive net income quarter [4][6][9] Financial Performance - Fourth-quarter 2025 revenue was $208.9 million, a 27.1% increase year over year, while full-year revenue reached $747.1 million, up 26.2% compared to 2024 [3][6] - Gross margin for Q4 was 70.9%, up 90 basis points year over year, and full-year gross margin was 70.6%, an increase of 170 basis points [1][6] - Operating expenses in Q4 rose to $145.8 million from $119.2 million a year earlier, with full-year operating expenses totaling $584.7 million, up 11.8% [7] - The company achieved its first positive quarterly net income of $5.6 million in Q4, while recording a full-year net loss of $44.6 million [7][9] Market Positioning - iRhythm holds approximately 72% market share in long-term monitoring and over one-third of volume from primary care, with strong EHR integration [5][10] - The company serves around 40,000 primary care physicians, emphasizing a complementary approach to cardiology [11] Product Development - The next-generation mobile cardiac telemetry (MCT) device is under FDA review, expected to launch in H1 2027, featuring a mobile gateway [15][16] - The current MCT offering, Zio AT, has shown unit growth exceeding 50% for the year [14] International Expansion - iRhythm is operational in the U.K., select E.U. markets, and Japan, with plans for growth in these regions expected to outpace overall company growth in 2026 [17][18] 2026 Guidance - Management guided for 2026 revenue of $870 million to $880 million, representing 16% to 18% growth, with an adjusted EBITDA margin of 11.5% to 12.5% [6][20][21] - Pricing is expected to remain flat in 2026, with Medicare rates for long-term monitoring increasing but MCT category rates slightly decreasing [22] Regulatory Considerations - Management addressed concerns regarding heightened scrutiny of chart-derived diagnoses, suggesting that iRhythm's services could reduce audit exposure [23]

分组1 - iRhythm Holdings, Inc. (IRTC) reported quarterly earnings of $0.29 per share, significantly exceeding the Zacks Consensus Estimate of $0.02 per share, and compared to earnings of $0.01 per share a year ago, representing an earnings surprise of +1,484.70% [1] - The company posted revenues of $208.89 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.29%, and this is an increase from year-ago revenues of $164.32 million [2] - iRhythm Holdings has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times in the same period [2] 分组2 - The stock has underperformed the market, losing about 13.3% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.46 on revenues of $192.01 million, and for the current fiscal year, it is -$0.43 on revenues of $868.94 million [7] - The Medical Info Systems industry, to which iRhythm Holdings belongs, is currently in the bottom 46% of the Zacks industries, indicating potential challenges for stock performance [8]

Financial Data and Key Metrics Changes - iRhythm reported Q4 2025 revenue of $208.9 million, representing a 27.1% year-over-year growth, and full year 2025 revenue of $747.1 million, reflecting a 26.2% growth compared to 2024 [19][20] - The company achieved its first positive net income in Q4 2025, amounting to $5.6 million, or $0.17 per diluted share, while the full year net loss was $44.6 million, or a loss of $1.39 per diluted share [22] - Adjusted EBITDA for Q4 was $34.3 million, or 16.4% of revenue, marking a 470 basis point improvement year-over-year, and full year adjusted EBITDA was $68.9 million, or 9.2% of revenue, an improvement of over 1,000 basis points compared to 2024 [23] Business Line Data and Key Metrics Changes - The growth in Q4 was primarily driven by sustained volume demand across customer bases, with new store growth accounting for approximately 68% of year-over-year volume growth [20][21] - The Zio AT offering performed exceptionally well, with unit growth running more than twice the company average for the year [12][13] - The company holds approximately 15% market share in the MCT market, compared to 72% in long-term cardiac monitoring [14] Market Data and Key Metrics Changes - iRhythm serves approximately 40,000 primary care physicians, with more than one-third of volume originating from primary care settings [9] - The company is now commercial in the U.K., select E.U. markets, and Japan, where it holds less than 1% market share, indicating significant growth potential [14][15] - The U.K. market saw the largest quarter of volume ever for iRhythm, and the company is participating in NHS pilots [14] Company Strategy and Development Direction - iRhythm aims to shift from episodic detection to proactive, integrated, and predictive care, addressing the need for long-term continuous monitoring [8] - The company plans to focus on durable, volume-led growth across cardiology, primary care, and innovative channels, while expanding margins through operational efficiencies [16] - The strategic direction includes advancing platform innovation, scaling international markets, and maintaining operational excellence [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver durable growth while expanding profitability, emphasizing the importance of addressing rising clinical needs and constrained access in healthcare [28][29] - The company anticipates revenue for 2026 to be in the range of $870 million-$880 million, representing 16%-18% year-over-year growth [24] - Management highlighted the importance of integrating EHR systems and predictive AI capabilities to enhance patient care and operational efficiency [10][11] Other Important Information - 2025 marked the first year of positive adjusted EBITDA and free cash flow in the company's history, demonstrating profitable growth [23][24] - The company is actively working on a next-generation MCT device, expected to be released in the first half of 2027, which will feature a 21-day wear time and enhanced algorithms [13][56] - iRhythm is positioned at the intersection of several trends, including an aging population and increasing demand for proactive health management [15] Q&A Session Summary Question: Concerns about the elimination of chart-derived diagnosis from CMS - Management addressed concerns by stating that Zio provides confirmatory diagnoses, which is crucial for integration into patient records and audit processes [32][33] Question: Guidance on gross and operating margins for 2026 - Management provided guidance for adjusted EBITDA margin of 11.5%-12.5% for 2026 and expected gross margin improvement of 80-100 basis points relative to 2025 [37] Question: Potential tailwind from CMS proposals regarding chart scraping - Management indicated that the confirmatory diagnosis provided by Zio could serve as a tailwind, as partners are focused on improving documentation and reducing costs [40][41] Question: International growth assumptions for 2026 - Management expects international growth to slightly exceed overall company growth, with significant potential in newly opened markets [43] Question: AI concerns and billing implications - Management expressed confidence in their closed platform and the quality of data, emphasizing that AI capabilities must fit within existing workflows [48][49] Question: Updates on the MCT product timeline and enhancements - Management confirmed that the MCT product is on track for a first half 2027 release, with significant enhancements including a mobile gateway and improved algorithms [55][56]

Financial Data and Key Metrics Changes - iRhythm reported Q4 2025 revenue of $208.9 million, representing a 27.1% year-over-year growth, and full year 2025 revenue of $747.1 million, reflecting a 26.2% growth compared to 2024 [19][20] - Gross margin for Q4 was 70.9%, an increase of 90 basis points year-over-year, while full year gross margin was 70.6%, an improvement of 170 basis points year-over-year [21] - The company achieved its first positive net income in Q4 2025, amounting to $5.6 million, or $0.17 per diluted share, while the full year net loss was $44.6 million, or a loss of $1.39 per diluted share [22] - Adjusted EBITDA for Q4 was $34.3 million, or 16.4% of revenue, marking a 470 basis point improvement year-over-year, and full year adjusted EBITDA was $68.9 million, or 9.2% of revenue, representing an improvement of over 1,000 basis points compared to 2024 [23][24] Business Line Data and Key Metrics Changes - The growth in Q4 was driven by sustained volume demand across all channels, with new store growth accounting for approximately 68% of year-over-year volume growth [20] - The Zio AT offering performed exceptionally well, with unit growth running more than twice the company average for the year [12][14] - The company serves approximately 40,000 primary care physicians, with more than one-third of volume originating in primary care settings [9] Market Data and Key Metrics Changes - iRhythm holds a 72% market share in long-term continuous monitoring, with the segment growing in the high teens [7] - International markets represent a significant growth opportunity, with the company now commercial in the U.K., select E.U. markets, and Japan, where it holds less than 1% market share [14][15] - The U.K. delivered the largest quarter of volume ever for iRhythm, and the company is participating in pilots under the NHS Supply Chain's value-based procurement program [14] Company Strategy and Development Direction - The company aims to shift from episodic detection to proactive, integrated, and increasingly predictive care, addressing the need for long-term continuous monitoring [8] - iRhythm's strategy includes expanding margins through operational efficiencies, advancing platform innovation, and scaling international and adjacent markets [16] - The company is focused on delivering durable, volume-led growth across cardiology, primary care, and innovative channels while maintaining operational excellence [16][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver another year of durable, volume-led growth while expanding profitability [29] - The company is well-positioned to lead market expansion, driven by trends such as an aging population and increasing prevalence of arrhythmias [15][16] - Management highlighted the importance of confirmatory diagnoses in the context of recent regulatory scrutiny and expressed optimism about the potential tailwinds from these changes [17][41] Other Important Information - 2026 marks iRhythm's twentieth anniversary, with a goal to become a billion-dollar company by 2027 [18] - The company expects revenue for full year 2026 to be in the range of $870 million-$880 million, representing 16%-18% year-over-year growth [24][25] Q&A Session Summary Question: Concerns about the elimination of chart-derived diagnosis from CMS - Management addressed concerns by emphasizing that Zio provides confirmatory diagnoses, which is crucial for compliance and documentation [32][34] Question: Guidance on gross and operating margins for 2026 - Management provided guidance for adjusted EBITDA margin of 11.5%-12.5% for 2026 and expected gross margin improvement of 80-100 basis points relative to 2025 [37] Question: Potential tailwind from CMS proposals regarding chart scraping - Management indicated that the confirmatory diagnosis aspect of Zio could serve as a tailwind, although no specific assumptions were factored into forward-looking expectations [40][41] Question: AI concerns and potential impact on billing - Management expressed confidence in their unique data and regulatory position, stating that their platform's closed nature and established workflows would mitigate risks associated with AI adoption [48][49] Question: Updates on MCT product timeline and features - Management confirmed that the next-generation MCT device is expected to launch in the first half of 2027, featuring a mobile gateway and enhanced algorithms [56][57] Question: Guidance on international growth for 2026 - Management indicated that international growth is expected to slightly outpace overall company growth, with significant potential in newly opened markets [43]

Revenue Sources and Financial Performance - Approximately 24% of total revenue for the year ended December 31, 2025, was derived from the Medicare program through CMS[139]. - Revenue from non-contracted third-party commercial payors accounted for approximately 7% of total revenue for the year ended December 31, 2025, leading to limited visibility on payment timelines[247]. - The company has a history of operating losses and may not achieve or sustain profitability in the future[248]. - The company incurred net losses of $44.6 million and $113.3 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $803.4 million as of December 31, 2025[249]. - The company’s revenue and operating results may fluctuate significantly from quarter to quarter, influenced by factors such as seasonal variations in prescription rates[245]. Regulatory Compliance and Risks - The company faces risks related to compliance with Medicare regulations, which could result in penalties or loss of reimbursement if not adhered to[140]. - The evolving regulatory landscape may increase the risk of questions regarding the appropriateness of CPT codes used for billing[150]. - The billing process for iRhythm Services is complex and highly regulated, requiring substantial time and resources, with potential penalties for non-compliance impacting business operations[156]. - The company must navigate extensive compliance requirements for its medical devices, with non-compliance potentially leading to significant enforcement actions and financial impacts[172]. - The company is facing increased scrutiny regarding compliance with healthcare laws, which could lead to legal expenses and management distraction[221]. Competition and Market Dynamics - The market for remote cardiac monitoring solutions is highly competitive, with significant competition from both large manufacturers and smaller regional service providers[153]. - The company competes with large medical device companies and tech firms entering the digital health space, which could impact market share[155]. - The competitive landscape for medical devices is dynamic, and failure to innovate could lead to obsolescence of the company's services and decline in revenue[195]. - The company emphasizes the need for continuous development of new product offerings and enhancements to its iRhythm Services to remain competitive[196]. Research and Development - The company is in various stages of research and development for new diagnostic solutions, but there is no assurance of successful commercialization[152]. - The company has faced challenges in maintaining adequate research and development resources, which are essential for competitive positioning in the market[196]. - The company is focused on proactive monitoring of undiagnosed arrhythmias, but there are risks that the clinical community may not adopt the necessary screening criteria[210]. - The company may pursue acquisitions of complementary companies or technologies, but there is no guarantee that these will result in commercially viable products or significant future revenues[211]. Supply Chain and Operational Risks - The company relies heavily on iRhythm Services for revenue, which is expected to account for substantially all revenue for the foreseeable future[152]. - The company relies on third-party vendors for critical components of the iRhythm ACM Systems, exposing it to risks related to supply chain disruptions[188]. - The company may experience production delays due to reliance on single suppliers for key components, which could impair its ability to meet demand for iRhythm Services[189]. - The company faces risks related to manufacturing an adequate supply of iRhythm ACM Systems to meet demand and maintain quality[250]. Cybersecurity and Data Protection - Cybersecurity risks, including data breaches and service interruptions, could compromise confidential data and lead to significant remediation costs and reputational damage[280]. - A recent cybersecurity incident involving a third-party vendor caused a temporary delay in billing, impacting cash collections[281]. - The evolving nature of cyber threats may require the company to allocate significant resources to enhance protective measures and address vulnerabilities[284]. - Compliance with various cybersecurity regulations is critical, as failure to meet these standards could lead to enforcement actions, product recalls, or operational disruptions[287]. Financial Management and Capital Structure - The company may require additional capital to support growth, which might not be available on acceptable terms, potentially leading to dilution for stockholders[251]. - The company is exposed to risks related to its increased debt, which may adversely affect its financial health and operational flexibility[305]. - Servicing the company's debt requires significant cash flow, which may not be sufficient in the future to meet its obligations[307]. - The conversion of the 2029 Notes may dilute existing stockholders' ownership interests and potentially depress stock prices[313]. International Expansion and Regulatory Compliance - International expansion efforts are focused on markets such as the Philippines, the EU, the UK, Switzerland, and Japan, but these efforts expose the company to various operational and regulatory risks[200]. - The company faces significant risks associated with compliance with multiple international regulations, including the UK MDR and EU AI Act, which could impact its operations and market access[207]. Legal and Intellectual Property Risks - The company faces risks related to intellectual property infringement claims, which could lead to significant costs and operational disruptions[266]. - Numerous patents issued to third parties may relate to the company's iRhythm ACM Systems, increasing the risk of infringement claims as competition in the remote cardiac monitoring market grows[267]. - If found to infringe on patents, the company could incur substantial damages, including potential treble damages for willful infringement, which could adversely affect financial conditions[271]. Future Outlook and Strategic Initiatives - The company is exploring opportunities to expand into the sleep apnea screening and diagnostics market, which requires significant investment and carries unique regulatory requirements[215]. - The company anticipates that new products developed from BioIS's technologies will require validation and regulatory approval, impacting commercialization timelines[214]. - The company does not expect meaningful revenue from sleep apnea opportunities in the near future, risking competitive threats if competitors act more quickly[215].